(Reuters)-Australia’s biotechnology CSL announced on Thursday that it had agreed to produce about 50 million doses of AstraZeneca (NASDAQ :) COVID-19 vaccine by 2022.
The announcement came after the media reported that Vaxzevria, a vaccine from a British pharmaceutical company, would no longer be manufactured due to demand for vaccines in Australia. Pfizer (NYSE :) and Modana (NASDAQ :). [nL4N2R91XR]
Pfizer and Modana have established a market advantage by using mRNA-based COVID-19 vaccine technology to combat pandemics.
The CSL added in a brief statement that more than 20 million doses have already been produced and the rest of the production is expected to be completed early next year.
Sydney’s cafes, gyms and restaurants welcomed fully vaccinated customers earlier this week as Australia aims to begin living with the coronavirus and gradually resume with high vaccination rates.
Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Australia’s CSL reaffirms Reuters’ commitment to producing the AstraZeneca COVID vaccine.
Source link Australia’s CSL reaffirms Reuters’ commitment to producing the AstraZeneca COVID vaccine.